Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest announcement is out from Hansa Biopharma AB ( (SE:HNSA) ).
Hansa Biopharma has entered into an exclusive €115 million licensing deal with SERB Pharmaceuticals for the development and commercialization of its first-in-class antibody-cleaving therapy IDEFIRIX across the EU, UK, Switzerland, Norway, Liechtenstein, Iceland and the MENA region. Under the agreement, SERB will take over regional commercialization and long-term post-authorization studies in transplantation, while Hansa secures a significant upfront payment that strengthens its balance sheet and supports a planned U.S. launch and pathway to profitability, contingent on regulatory approvals.
The arrangement is positioned as transformative for Hansa, crystallizing the value of its IDEFIRIX franchise while allowing a specialist partner with a strong commercial footprint in critical care and rare diseases to broaden patient access in Europe and MENA. By shifting regional responsibilities for follow-up studies and pediatric development to SERB once market authorization is transferred, Hansa can focus resources on its U.S. strategy and R&D pipeline, while SERB aims to expand treatment options for highly sensitized kidney transplant candidates who face limited alternatives today.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK103.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a Sweden-based biopharmaceutical company focused on rare immunologic diseases and transplantation, developing innovative antibody-degrading enzymes such as IDEFIRIX for highly sensitized kidney transplant patients. SERB Pharmaceuticals is a privately owned global specialty pharma group with a strong European presence, focusing on rare diseases, critical care, and medical countermeasures with a portfolio of over 70 products across 18 countries.
Average Trading Volume: 354,427
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK3.02B
For an in-depth examination of HNSA stock, go to TipRanks’ Overview page.